|
1
|
Zhai Z, Zheng Y, Li N, Deng Y, Zhou L,
Tian T, Yang S, Hao Q, Song D, Wu Y, et al: Incidence and disease
burden of prostate cancer from 1990 to 2017: Results from the
Global Burden of Disease Study 2017. Cancer. 126:1969–1978. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giona S: The Epidemiology of Prostate
Cancer. Prostate Cancer Exon Publications; Australia: pp. 1–16.
2021
|
|
3
|
Liu Y, Hegde P, Zhang F, Hampton G and Jia
S: Prostate cancer-a biomarker perspective. Front Endocrinol
(Lausanne). 3:722012. View Article : Google Scholar
|
|
4
|
Christensen E, Evans KR, Menard C,
Pintilie M and Bristow RG: Practical approaches to proteomic
biomarkers within prostate cancer radiotherapy trials. Cancer
Metastasis Rev. 27:375–385. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schroder FH, Hugosson J, Carlsson S,
Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F and
Roobol MJ: Screening for prostate cancer decreases the risk of
developing metastatic disease: Findings from the European
Randomized study of screening for prostate cancer (ERSPC). Eur
Urol. 62:745–752. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang Y, Chisholm GD and Habib FK: The
distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the
prostate. Prostate. 21:201–208. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elgamal AA, Cornillie FJ, Van Poppel HP,
Van de Voorde WM, McCabe R and Baert LV: Free-to-total prostate
specific antigen ratio as a single test for detection of
significant stage T1c prostate cancer. J Urol. 156:1042–1047;
discussion 1047-1049. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aksoy Y, Oral A, Aksoy H, Demirel A and
Akcay F: PSA density and PSA transition zone density in the
diagnosis of prostate cancer in PSA gray zone cases. Ann Clin Lab
Sci. 33:320–323. 2003.PubMed/NCBI
|
|
9
|
Elgamal AA, Ectors NL, Sunardhi-Widyaputra
S, Van Poppel HP, Van Damme BJ and Baert LV: Detection of prostate
specific antigen in pancreas and salivary glands: A potential
impact on prostate cancer overestimation. J Urol. 156(2 Pt 1):
464–468. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin J, Zhan T, Duffy D, Hoffman-Censits J,
Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K,
Kennedy B, et al: A pilot phase II Study of digoxin in patients
with recurrent prostate cancer as evident by a rising PSA. Am J
Cancer Ther Pharmacol. 2:21–32. 2014.
|
|
11
|
Vickers AJ, Cronin AM, Aus G, Pihl CG,
Becker C, Pettersson K, Scardino PT, Hugosson J and Lilja H: Impact
of recent screening on predicting the outcome of prostate cancer
biopsy in men with elevated prostate-specific antigen: Data from
the European Randomized Study of Prostate Cancer Screening in
Gothenburg, Sweden. Cancer. 116:2612–2620. 2010.PubMed/NCBI
|
|
12
|
Pelzer AE, Tewari A, Bektic J, Berger AP,
Frauscher F, Bartsch G and Horninger W: Detection rates and
biologic significance of prostate cancer with PSA less than 4.0
ng/mL: observation and clinical implications from Tyrol screening
project. Urology. 66:1029–1033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sella A, Konichezky M, Flex D, Sulkes A
and Baniel J: Low PSA metastatic androgen-independent prostate
cancer. Eur Urol. 38:250–254. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pepe P, Panella P, Savoca F, Cacciola A,
D'Arrigo L, Dibenedetto G, Pennisi M and Aragona F: Prevalence and
clinical significance of prostate cancer among 12,682 men with
normal digital rectal examination, low PSA levels (< or =4
ng/ml) and percent free PSA cutoff values of 15 and 20%. Urol Int.
78:308–312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trotz C: Prostate cancer with a normal
PSA: Small cell carcinoma of the prostate-a rare entity. J Am Board
Fam Pract. 16:343–344. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chien J and Shah GV: Role of stimulatory
guanine nucleotide binding protein (GSalpha) in proliferation of
PC-3M prostate cancer cells. Int J Cancer. 91:46–54. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thomas S, Chigurupati S, Anbalagan M and
Shah G: Calcitonin increases tumorigenicity of prostate cancer
cells: Evidence for the role of protein kinase A and urokinase-type
plasminogen receptor. Mol Endocrinol. 20:1894–1911. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aljameeli A, Thakkar A, Thomas S,
Lakshmikanthan V, Iczkowski KA and Shah GV: Calcitonin
receptor-zonula occludens-1 interaction is critical for
calcitonin-stimulated prostate cancer metastasis. PLoS One.
11:e01500902016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kale A, Aldahish A and Shah G: Calcitonin
receptor is required for T-antigen-induced prostate carcinogenesis.
Oncotarget. 11:858–874. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shah GV, Muralidharan A, Gokulgandhi M,
Soan K and Thomas S: Cadherin switching and activation of
beta-catenin signaling underlie proinvasive actions of
calcitonin-calcitonin receptor axis in prostate cancer. J Biol
Chem. 284:1018–1030. 2009. View Article : Google Scholar :
|
|
21
|
Shah GV, Thomas S, Muralidharan A, Liu Y,
Hermonat PL, Williams J and Chaudhary J: Calcitonin promotes in
vivo metastasis of prostate cancer cells by altering cell
signaling, adhesion, and inflammatory pathways. Endocr Relat
Cancer. 15:953–964. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aldahish A, Kale A, Aljameeli A and Shah
GV: Calcitonin induces stem cell-like phenotype in prostate cancer
cells. Endocr Relat Cancer. 26:815–828. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shah GV, Noble MJ, Austenfeld M, Weigel J,
Deftos LJ and Mebust WK: Presence of calcitonin-like
immunoreactivity (iCT) in human prostate gland: Evidence for iCT
secretion by cultured prostate cells. Prostate. 21:87–97. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aljameeli A, Thakkar A and Shah G:
Calcitonin receptor increases invasion of prostate cancer cells by
recruiting zonula occludens-1 and promoting PKA-mediated TJ
disassembly. Cell Signal. 36:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schweinfest C and Papas T: Subtraction
hybridization-an approach to the isolation of genes differentially
expressed in cancer and other biological-systems. Int J Oncol.
1:499–506. 1992.PubMed/NCBI
|
|
26
|
Ren Y, Sun YP and Shah GV: Calcitonin
inhibits prolactin promoter activity in rat pituitary GGH3 cells:
Evidence for the involvement of p42/44 mitogen-activated protein
kinase in calcitonin action. Endocrine. 20:13–22. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren Y, Chien J, Sun YP and Shah GV:
Calcitonin is expressed in gonadotropes of the anterior pituitary
gland: Its possible role in paracrine regulation of lactotrope
function. J Endocrinol. 171:217–228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma J, Feng Y, Xie W and Li X: PP2A (PR65)
in Silver Carp: cDNA cloning and expression analysis. J Biochem Mol
Toxicol. 29:399–409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Panoskaltsis-Mortari A and Bucy RP: In
situ hybridization with digoxigenin-labeled RNA probes: Facts and
artifacts. Biotechniques. 18:300–307. 1995.PubMed/NCBI
|
|
34
|
Gupta A and Pulliam L: Exosomes as
mediators of neuroinflammation. J Neuroinflammation. 11:682014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wiles HB, Bricker JT, Cooley DA, Nihill
MR, Frazier OH, Waldenberger F and McNamara DG: Repeated
endomyocardial biopsy without complication in an infant after heart
transplantation. J Thorac Cardiovasc Surg. 91:637–638. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chien J, Wong E, Nikes E, Noble MJ,
Pantazis CG and Shah GV: Constitutive activation of stimulatory
guanine nucleotide binding protein (G(S)alphaQL)-mediated signaling
increases invasiveness and tumorigenicity of PC-3M prostate cancer
cells. Oncogene. 18:3376–3382. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Alzghoul S, Hailat M, Zivanovic S, Que L
and Shah GV: Measurement of serum prostate cancer markers using a
nanopore thin film based optofluidic chip. Biosens Bioelectron.
77:491–498. 2016. View Article : Google Scholar
|
|
38
|
Shah GV, Deftos LJ and Crowley WR:
Synthesis and release of calcitonin-like immunoreactivity by
anterior pituitary cells: Evidence for a role in paracrine
regulation of prolactin secretion. Endocrinology. 132:1367–1372.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cai MJ, Zhan FX, Kong XN, Zhu SZ, Cui Y
and Wang Q: RING domain of zinc finger protein like 1 is essential
for cell proliferation in endometrial cancer cell line RL95-2.
Gene. 677:17–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thakkar A, Bijnsdorp IV, Geldof AA and
Shah GV: Profiling of the calcitonin-calcitonin receptor axis in
primary prostate cancer: Clinical implications and molecular
correlates. Oncol Rep. 30:1265–1274. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Thomas S and Shah G: Calcitonin induces
apoptosis resistance in prostate cancer cell lines against
cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther.
4:1226–1233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fedotova AA, Bonchuk AN, Mogila VA and
Georgiev PG: C2H2 zinc finger proteins: The largest but poorly
explored family of higher eukaryotic transcription factors. Acta
Naturae. 9:47–58. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hoppener JW, De Wit MJ, Simarro-Doorten
AY, Roijers JF, van Herrewaarden HM, Lips CJ, Parente F, Quincey D,
Gaudray P, Khodaei S, et al: A putative human zinc-finger gene
(ZFPL1) on 11q13, highly conserved in the mouse and expressed in
exocrine pancreas. The European Consortium on MEN 1. Genomics.
50:251–259. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Klap J, Schmid M and Loughlin KR: The
relationship between total testosterone levels and prostate cancer:
A review of the continuing controversy. J Urol. 193:403–413. 2015.
View Article : Google Scholar
|
|
45
|
Shah GV: Calcitonin. Encyclopedia of
Cancer. 2:16–20. 2009.
|
|
46
|
Nakamura N: Emerging new roles of GM130, a
cis-Golgi matrix protein, in higher order cell functions. J
Pharmacol Sci. 112:255–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sun X, Tie HC, Chen B and Lu L: Glycans
function as a Golgi export signal to promote the constitutive
exocytic trafficking. J Biol Chem. 295:14750–14762. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chiu CF, Ghanekar Y, Frost L, Diao A,
Morrison D, McKenzie E and Lowe M: ZFPL1, a novel ring finger
protein required for cis-Golgi integrity and efficient ER-to-Golgi
transport. EMBO J. 27:934–947. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Appetecchia M, Lauretta R, Sperduti I and
Gallucci M: Chromogranin A as a biomarker for prostate cancer: Is
it actually relevant for clinical practice? Future Oncol.
14:1233–1235. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Morath I, Hartmann TN and Orian-Rousseau
V: CD44: More than a mere stem cell marker. Int J Biochem Cell
Biol. 81(Pt A): 166–173. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Iczkowski KA: Cell adhesion molecule CD44:
Its functional roles in prostate cancer. Am J Transl Res. 3:1–7.
2010.PubMed/NCBI
|
|
52
|
van Leenders GJ, Sookhlall R, Teubel WJ,
de Ridder CM, Reneman S, Sacchetti A, Vissers KJ, van Weerden W and
Jenster G: Activation of c-MET induces a stem-like phenotype in
human prostate cancer. PLoS One. 6:e267532011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kong D, Sethi S, Li Y, Chen W, Sakr WA,
Heath E and Sarkar FH: Androgen receptor splice variants contribute
to prostate cancer aggressiveness through induction of EMT and
expression of stem cell marker genes. Prostate. 75:161–174. 2015.
View Article : Google Scholar
|
|
54
|
Sanchez BG, Bort A, Vara-Ciruelos D and
Diaz-Laviada I: Androgen deprivation induces reprogramming of
prostate cancer cells to stem-like cells. Cells. 9:14412020.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cerasuolo M, Paris D, Iannotti FA, Melck
D, Verde R, Mazzarella E, Motta A and Ligresti A: Neuroendocrine
transdifferentiation in human prostate cancer cells: An integrated
approach. Cancer Res. 75:2975–2986. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dhavale M, Abdelaal MK, Alam ABMN, Blazin
T, Mohammed LM, Prajapati D, Ballestas NP and Mostafa JA: Androgen
receptor signaling and the emergence of lethal neuroendocrine
prostate cancer with the treatment-induced suppression of the
androgen receptor: A literature review. Cureus.
13:e134022021.PubMed/NCBI
|
|
57
|
Ito T, Yamamoto S, Ohno Y, Namiki K,
Aizawa T, Akiyama A and Tachibana M: Up-regulation of
neuroendocrine differentiation in prostate cancer after androgen
deprivation therapy, degree and androgen independence. Oncol Rep.
8:1221–1224. 2001.PubMed/NCBI
|
|
58
|
Chen R, Dong X and Gleave M: Molecular
model for neuroendocrine prostate cancer progression. BJU Int.
122:560–570. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Rubin MA, Bristow RG, Thienger PD, Dive C
and Imielinski M: Impact of lineage plasticity to and from a
neuroendocrine phenotype on progression and response in prostate
and lung cancers. Mol Cell. 80:562–577. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Faugeroux V, Pailler E, Oulhen M, Deas O,
Brulle-Soumare L, Hervieu C, Marty V, Alexandrova K, Andree KC,
Stoecklein NH, et al: Genetic characterization of a unique
neuroendocrine transdifferentiation prostate circulating tumor
cell-derived eXplant model. Nat Commun. 11:18842020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Gupta K and Gupta S: Neuroendocrine
differentiation in prostate cancer: Key epigenetic players. Transl
Cancer Res. 6(Suppl 1): S104–S108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Aggarwal R, Huang J, Alumkal JJ, Zhang L,
Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, et
al: Clinical and genomic characterization of treatment-emergent
small-cell neuroendocrine prostate cancer: A multi-institutional
prospective study. J Clin Oncol. 36:2492–2503. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Aggarwal R, Zhang T, Small EJ and
Armstrong AJ: Neuroendocrine prostate cancer: Subtypes, biology,
and clinical outcomes. J Natl Compr Canc Netw. 12:719–726. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Aggarwal RR and Small EJ:
Small-cell/neuroendocrine prostate cancer: A growing threat?
Oncology (Williston Park). 28:838–840. 2014.PubMed/NCBI
|
|
65
|
Denzer K, Kleijmeer MJ, Heijnen HF,
Stoorvogel W and Geuze HJ: Exosome: From internal vesicle of the
multivesicular body to intercellular signaling device. J Cell Sci.
113(Pt 19): 3365–3374. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
McAndrews KM and Kalluri R: Mechanisms
associated with biogenesis of exosomes in cancer. Mol Cancer.
18:522019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Bang C and Thum T: Exosomes: New players
in cell-cell communication. Int J Biochem Cell Biol. 44:2060–2064.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rappa G, Mercapide J, Anzanello F, Pope RM
and Lorico A: Biochemical and biological characterization of
exosomes containing prominin-1/CD133. Mol Cancer. 12:622013.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Cindolo L, Cantile M, Vacherot F, Terry S
and de la Taille A: Neuroendocrine differentiation in prostate
cancer: From lab to bedside. Urol Int. 79:287–296. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Beltran H, Rickman DS, Park K, Chae SS,
Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, et
al: Molecular characterization of neuroendocrine prostate cancer
and identification of new drug targets. Cancer Discov. 1:487–495.
2011. View Article : Google Scholar
|
|
71
|
Terry S and Beltran H: The many faces of
neuroendocrine differentiation in prostate cancer progression.
Front Oncol. 4:602014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Thomas S, Muralidharan A and Shah GV:
Knock-down of calcitonin receptor expression induces apoptosis and
growth arrest of prostate cancer cells. Int J Oncol. 31:1425–1437.
2007.PubMed/NCBI
|
|
73
|
Pompura SL and Dominguez-Villar M: The
PI3K/AKT signaling pathway in regulatory T-cell development,
stability, and function. J Leukoc Biol. Jan 22–2018.Epub ahead of
print. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bluemn EG, Paulson KG, Higgins EE, Sun Y,
Nghiem P and Nelson PS: Merkel cell polyomavirus is not detected in
prostate cancers, surrounding stroma, or benign prostate controls.
J Clin Virol. 44:164–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
